GlassScriptPhysician profile
Stephanie A Cassady
NPI 1376541367
$1,492.95
in general payments reported to CMS, 2019-2025
20 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $205 · 2023: $390 · 2024: $334 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $257.42 | 2022-2025 | General - Therapies, Wavewriter Alpha Prime 16, Patient Trial Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.14 | 2021-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $207.33 | 2021-2025 | |
| Novo Nordisk INC | $141.50 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $90.41 | 2023-2025 | |
| Pfizer INC. | $85.67 | 2021-2025 | |
| Amgen INC. | $85.43 | 2023-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $76.07 | 2022-2024 | |
| Glaxosmithkline, LLC. | $63.92 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $57.70 | 2021-2025 | Zepbound, Mounjaro |
| Eisai INC. | $54.91 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $21.66 | 2024 | Gemtesa |
| Medtronic, INC. | $20.45 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.38 | 2022 | |
| Dexcom, INC. | $19.85 | 2023 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $19.83 | 2024 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $17.96 | 2025 | Farxiga |
| Lundbeck LLC | $14.26 | 2023 | Vyepti |
| Antares Pharma, INC. | $14.08 | 2022 | |
| Tolmar, INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Cassady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.